Treatment outcome and safety of anti-PD-1 antibody against elderly non-small cell lung cancer.

被引：0
|
作者：
Sakatani, Toshio
Saihara, Aya
Ikushima, Hiroaki
Takeshima, Hideyuki
Taniguchi, Yuri
Hojo, Masayuki
Usui, Kazuhiro
机构：
[1] NTT Med Ctr Tokyo, Tokyo, Japan
[2] Kanto Med Ctr NTT EC, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e14249
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14249
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Efficacy and Safety of Anti-PD-1 Inhibitors in Elderly Patients with Advanced Non-Small Cell Lung Cancer
    Tanaka, Y.
    Okano, T.
    Kudo, Y.
    Takeuchi, S.
    Makino, Y.
    Shimada, Y.
    Maehara, S.
    Hagiwara, M.
    Kakihana, M.
    Kajiwara, N.
    Ohira, T.
    Ikeda, N.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S979 - S980
  • [2] Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC)
    Liu, Si-Yang
    Wu, Yi-Long
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (12) : 1355 - 1363
  • [3] The Efficacy and Safety of Anti-PD-1 in the Treatment of Non-Small Cell Lung Cancer (NSCLC): Systematic Review
    Di, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1917 - S1917
  • [4] CLINICAL MANIFESTATIONS OF ADRENAL INSUFFICIENCY AFTER ANTI-PD-1 ANTIBODY TREATMENT IN NON-SMALL CELL LUNG CANCER
    Hamada, Kentaro
    Takahashi, Tamaki
    Megumu, Osaki
    Kojima, Ayaka
    Shima, Kazuki
    Yagi, Yoshitaka
    Fuseya, Yoshinori
    Nishioka, Michiyoshi
    Katakura, Hiromichi
    Sakai, Naoki
    RESPIROLOGY, 2019, 24 : 185 - 186
  • [5] Evaluation of the efficacy and safety of anti-PD-1 and anti-PD-L1 antibody in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis
    Jia, Minghan
    Feng, Weijiao
    Kang, Shiyang
    Zhang, Yaxiong
    Shen, Jianfei
    He, Jiaxi
    Jiang, Long
    Wang, Wei
    Guo, Zhihua
    Peng, Guilin
    Chen, Gang
    He, Jianxing
    Liang, Wenhua
    JOURNAL OF THORACIC DISEASE, 2015, 7 (03) : 455 - 461
  • [6] Retreatment with anti-PD-1 antibody in non-small cell lung cancer patients previously treated with anti-PD-L1 antibody
    Fujita, Kohei
    Yamamoto, Yuki
    Kanai, Osamu
    Okamura, Misato
    Hashimoto, Masayuki
    Nakatani, Koichi
    Sawai, Satoru
    Mio, Tadashi
    THORACIC CANCER, 2020, 11 (01) : 15 - 18
  • [7] Immunologic monitoring markers of clinical responses to anti-PD-1 therapy for non-small cell lung cancer.
    Oka, Mikio
    Kurose, Koji
    Ohue, Yoshihiro
    Karasaki, Takahiro
    Futami, Junichiro
    Masuda, Takeshi
    Fukuda, Masaaki
    Kinoshita, Akitoshi
    Shimizu, Katsuhiko
    Nakata, Masao
    Hattori, Noboru
    Yamaguchi, Hiroyuki
    Fukuda, Minoru
    Oga, Toru
    Kakimi, Kazuhiro
    CANCER IMMUNOLOGY RESEARCH, 2020, 8 (03) : 104 - 105
  • [8] DNA methylation profiles associated with response to anti-PD-1 immunotherapy in non-small cell lung cancer.
    Cho, Jae-Won
    Hong, Min Hee
    Ha, Sang-Jun
    Kim, Young-Joon
    Lee, Insuk
    Kim, Hye Ryun
    CANCER IMMUNOLOGY RESEARCH, 2020, 8 (03) : 33 - 33
  • [9] Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer
    Jensen, Kristian Hastoft
    Persson, Gitte
    Bondgaard, Anna-Louise
    Pohl, Mette
    ACTA ONCOLOGICA, 2018, 57 (08) : 1127 - 1128
  • [10] Anti-PD-1 With or Without Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer
    Teng, F.
    Wang, P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E455 - E456
12345